预约演示
更新于：2025-06-01
Minodronic Acid Hydrate
米诺膦酸
更新于：2025-06-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2009-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H14N2O8P2 |
InChIKeyGPAPAOGRNKUFGH-UHFFFAOYSA-N |
CAS号155648-60-5 |
关联
51
项与 米诺膦酸 相关的临床试验CTR20244081
米诺膦酸片在空腹给药条件下随机、开放、单剂量、四周期、完全重复交叉生物等效性试验
CTR20243020
米诺膦酸片（1mg）空腹人体生物等效性研究
CTR20244031
米诺膦酸片在空腹给药条件下随机、开放、单剂量、四周期、完全重复交叉生物等效性预试验
100 项与 米诺膦酸 相关的临床结果
登录后查看更多信息
100 项与 米诺膦酸 相关的转化医学
登录后查看更多信息
100 项与 米诺膦酸 相关的专利（医药）
登录后查看更多信息
314
项与 米诺膦酸 相关的文献（医药）2025-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition
Article
作者: Garg, Mohit ; Vasan, Seshadri S ; Sankaranarayanan, Murugesan ; Muzaffar-Ur-Rehman, Mohammed ; Chandu, Ala ; Kuthe, Pranali Vijaykumar ; Chougule, Kishor Suryakant
The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.
2024-09-01Current molecular medicine
Current Market Potential and Prospects of Copper-based Pyridine
Derivatives: A Review
Review
作者: Mishra, Rakhi ; Mazumder, Avijit ; Tyagi, Shivani ; Mazumder, Rupa
Abstract::
Nicotine, minodronic acid, nicotinamide (niacin), zolpidem, zolimidine, and
other pyridine-based chemicals play vital roles in medicine and biology. Pyridinecontaining
drugs are widely available on the market to treat a wide range of human
ailments. As a result of these advances, pyridine research is continually expanding, and
there are now higher expectations for how it may aid in the treatment of numerous
ailments. This evaluation incorporates data acquired from sources, like PubMed, to
provide a thorough summary of the approved drugs and bioactivity data for compounds
containing pyridine. Most of the reactions discussed in this article will provide readers
with a deeper understanding of various pyridine-related examples, which is necessary
for the creation of copper catalysis-based synthetic processes that are more accessible,
secure, environmentally friendly, and practical, and that also have higher accuracy and
selectivity. This paper also discusses significant innovations in the multi-component
copper-catalyzed synthesis of N-heterocycles (pyridine), with the aim of developing
precise, cost-effective, and environmentally friendly oxygenation and oxidation synthetic
methods for the future synthesis of additional novel pyridine base analogs. Therefore,
the review article will serve as a novel platform for researchers investigating copperbased
pyridine compounds.
2024-08-01Journal of Oral Implantology
Bone Augmentation With Alloplastic Graft Material in a Patient Under Bisphosphonate Therapy: A Case Report and Literature Review
Review
作者: Narahara, Shun ; Kuroshima, Shinichiro ; Shido, Rena ; Yamada, Tomohiro ; Yamanouch, Yuya ; Sawase, Takashi ; Ichinose, Sosuke ; Ohba, Seigo
Cases of relatively safe dental implant treatment in patients with low-volume bisphosphonate (BP) have been gradually reported. Although bone augmentation is commonly used when the bone volume is insufficient for implant placement, the studies and case reports regarding the safety of bone augmentation in patients treated with BP remain insufficient. Herein, we report a case wherein bone augmentation was performed after BP treatment with bone healing realized according to imaging, and we review the literature regarding BP and bone augmentation. A 67-year-old Japanese woman requested implant treatment for a hopeless lower right second molar. She had been taking minodronic acid hydrate (50 mg/4 wk) for 18 months to treat steroid-induced osteoporosis. After obtaining informed consent, tooth extraction and bone augmentation within the extraction socket were performed. The tooth was extracted atraumatically to preserve the surrounding alveolar bone, and the extraction socket was intensely curetted. Subsequently, the socket was filled with carbonate apatite granules and covered with a biodegradable membrane, and the wound was sutured without tension. Although protracted wound healing without any symptoms of infection was observed, the wound healed completely. No clinical symptoms were observed, the color of the mucosa at the site was healthy, and imaging findings at 6 months postoperation indicated that osteogenesis had progressed uneventfully.
100 项与 米诺膦酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 日本 | 2009-01-21 | |
| 骨质疏松症 | 日本 | 2009-01-21 | |
| 绝经期后骨质疏松 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性骨质疏松症 | 临床3期 | - | 2002-08-01 | |
| 原发性骨质疏松症 | 临床3期 | - | 2002-08-01 | |
| 高钙血症 | 临床3期 | 日本 | - | - |
| 多发性骨髓瘤 | 临床3期 | 日本 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 维持 intact parathyroid hormone levels | 20 | 簾憲鹽齋壓積鏇築餘網(構廠餘觸淵廠構網積鹹) = 餘憲膚繭繭願蓋餘鏇蓋 製顧餘鑰醖鏇網壓築繭 (夢願醖廠願積餘膚衊襯 ) 更多 | 积极 | 2019-06-13 | ||
Control (no minodronic acid) | 簾憲鹽齋壓積鏇築餘網(構廠餘觸淵廠構網積鹹) = 積製衊鏇膚餘顧繭網顧 製顧餘鑰醖鏇網壓築繭 (夢願醖廠願積餘膚衊襯 ) | ||||||
N/A | - | 築衊淵窪膚鑰衊醖顧餘(衊選艱遞選蓋繭獵襯獵) = 簾繭膚獵遞範簾繭簾網 壓壓膚醖鹽積艱夢窪壓 (醖鑰艱築鏇窪鏇襯選顧 ) 更多 | 积极 | 2016-05-17 | |||
Minodronate 50 mg/month | 築衊淵窪膚鑰衊醖顧餘(衊選艱遞選蓋繭獵襯獵) = 餘願鬱齋製簾積築獵鑰 壓壓膚醖鹽積艱夢窪壓 (醖鑰艱築鏇窪鏇襯選顧 ) 更多 | ||||||
临床3期 | 270 | 糧鏇鬱艱觸衊壓憲蓋憲(襯糧餘觸遞觸鬱憲壓鹽) = 繭簾蓋鏇醖鏇鑰構淵夢 繭蓋艱遞衊襯範簾構築 (憲窪淵獵淵窪簾積醖鏇 ) 更多 | - | 2009-06-01 | |||
Alendronate | 糧鏇鬱艱觸衊壓憲蓋憲(襯糧餘觸遞觸鬱憲壓鹽) = 醖觸糧齋醖鏇夢鏇衊廠 繭蓋艱遞衊襯範簾構築 (憲窪淵獵淵窪簾積醖鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用